Standard BioTools
LAB
112 hedge funds and large institutions have $249M invested in Standard BioTools in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 36 increasing their positions, 40 reducing their positions, and 20 closing their positions.
269% more call options, than puts
Call options by funds: $468K | Put options by funds: $127K
53% more capital invested
Capital invested by funds: $163M → $249M (+$86.6M)
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
9% more funds holding
Funds holding: 103 → 112 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.08% less ownership
Funds ownership: 91.05% → 87.97% (-3.1%)
10% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$10.1M |
| 2 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$4.35M |
| 3 |
Millennium Management
New York
|
+$3.37M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$2.94M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$20.3M |
| 2 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
-$12.4M |
| 3 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$2.78M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.61M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.84M |
LAB Hedge Fund Activity: Q2 2020 in Review
112 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2020, worth a combined $249M — up 53% from $163M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LAB positions and 20 closed out — a net gain of 10 holders — while 36 added to existing stakes and 40 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $10.1M. The largest seller was Russell Investments Group, cutting an estimated $20.3M.
- 112 institutional investors held Standard BioTools (LAB) as of Q2 2020, up from 103 in Q1 2020.
- Funds reported $249M of Standard BioTools stock for Q2 2020, up 53% quarter-over-quarter.
- 30 funds opened new Standard BioTools positions in Q2 2020 and 20 closed out, a net change of +10 holders.
- The largest Standard BioTools buyer in Q2 2020 was OrbiMed, an estimated $10.1M added.
- The largest Standard BioTools seller in Q2 2020 was Russell Investments Group, an estimated $20.3M sold.
Based on aggregated 13F filings for Q2 2020.